Modern Approaches to H. pylori Eradication Therapy in Adults (Literature Review and Resolution of Experts Council)
V. Т. Ivashkin,
A. I. Ulyanin,
I. V. Mayev,
R. S. Kozlov,
M. A. Livzan,
S. R. Abdulkhakov,
O. P. Alekseyeva,
S. A. Alekseyenko,
D. S. Bordin,
N. N. Dekhnich,
N. V. Korochyanskaya,
T. L. Lapina,
E. A. Poluektova,
V. I. Simanenkov,
A. S. Trukhmanov,
I. B. Khlynov,
V. V. Tsukanov,
A. A. Sheptulin https://doi.org/10.22416/1382-4376-2022-32-6-7-19
Abstract
Aim: to analyze current approaches to H. pylori eradication therapy in adults and present the materials of Experts Council held on December 9, 2022 in Moscow.
General statements. H. pylori infection is the main etiological factor of gastritis, peptic ulcer, and gastric cancer. Eradication of H. pylori is recognized as a necessary measure to reduce the incidence of these diseases. The approaches to selecting an eradication regimen should be optimized to take into account epidemiological trends and achieve better treatment outcomes. The updated Maastricht VI Consensus Report presents the means to overcome the difficulties in selecting an approach to the treatment of H. pylori infection. However, eradication therapy remains challenging due to adverse events (primarily antibiotic-associated diarrhea), poor treatment tolerance and patient compliance. Eradication therapy can be optimized by supplementing treatment regimens with strain-specific probiotics that reduce adverse events, improve patient compliance and eradication rates, such as Saccharomyces boulardii CNCM I-745 strain with established efficacy.
Conclusion. The inclusion of certain probiotics in eradication regimens improves treatment tolerance, reduces the risk of adverse events, improves patient compliance and eradication rates.
Keywords
gastritis,
gastric cancer,
atrophy,
H. pylori,
eradication,
compliance,
microbiome,
microbiota,
antibiotics,
probiotics,
Saccharomyces boulardii CNCM I-745
Supporting agencies: Council of Experts was hosted by pharmaceutical company Biocodex.
About the Authors
V. Т. Ivashkin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Vladimir T. Ivashkin — Dr. Sci. (Med.), RAS Academician, Prof., Departmental Head, Department of Propaedeutics of Internal Diseases, N.V. Chief of Vasilenko Clinic of Internal Disease Propaedeutics, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1, bld. 1
A. I. Ulyanin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Anatoly I. Ulyanin — Gastroenterologist, Department of Chronic Intestinal and Pancreatic Diseases, Vasilenko Clinic of Internal Disease Propaedeutics, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University).
119991, Moscow, Pogodinskaya str., 1, bld. 1
I. V. Mayev
A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Igor V. Maev — Dr. Sci. (Med.), Academician of the Russian Academy of Sciences, Professor, Head of the Department of Propaedeutics of Internal Diseases and Gastroenterology, A.I. Yevdokimov Moscow State University of Medicine and Dentistry.
127473, Moscow, Delegatskaya str., 20, bld. 1
R. S. Kozlov
Smolensk State Medical University
Russian Federation
Russian Federation
Roman S. Kozlov — Dr. Sci. (Med.), Prof., Corresponding Member of Russian Academy of Sciences (RAS), rector, Smolensk State Medical University, director, Research Institute of Antimicrobial Chemotherapy, President of the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC).
214019, Smolensk, Krupskoy str., 28
M. A. Livzan
Omsk State Medical University
Russian Federation
Russian Federation
Maria A. Livzan — Dr. Sci. (Med.), Prof., Corresponding Member of Russian Academy of Sciences (RAS); Head of the Chair of Faculty Therapy and Professional Diseases, Rector of Omsk State Medical University. Omsk State Medical University.
644099, Omsk, Lenina str., 12
SCOPUS Author ID: 24341682600
S. R. Abdulkhakov
Kazan (Volga Region) Federal University; Kazan State Medical University
Russian Federation
Russian Federation
Sayar R. Abdulkhakov — Cand. Sci. (Med.), Head of the Chair of Internal Diseases, Institute of Fundamental Medicine and Biology, Kazan Federal University; Assoc. Prof., Department (Chair) of Outpatient Therapy and General Medical Practice, Kazan State Medical University.
420012, Kazan, Kremlyovskaya str., 18
O. P. Alekseyeva
Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko
Russian Federation
Russian Federation
Olga P. Alekseeva — Dr. Sci. (Med.), Prof., Chair of Hospital Therapy and General Practice named after V.G. Vogralik, Privolzhsky Research Medical University.
603005, Nizhny Novgorod, Minina i Pozharskogo sq., 10/1
S. A. Alekseyenko
Far Eastern State Medical University
Russian Federation
Russian Federation
Sergey A. Alekseenko — Dr. Sci. (Med.), Head of the Department of Hospital Therapy, Far-Eastern State Medical University, Ministry of Health of the Russian Federation.
680000, Khabarovsk, Muravyova-Amurskogo str., 35
D. S. Bordin
A.I. Yevdokimov Moscow State University of Medicine and Dentistry; A.S. Loginov Moscow Clinical Scientific Center; Tver State Medical University
Russian Federation
Russian Federation
Dmitry S. Bordin — Dr. Sci. (Med.), Head of the Department of Pancreatic, Bile and Upper Gastrointestinal Pathology, Loginov Moscow Clinical Scientific Center; Prof., Department of Internal Medicine Propaedeutics and Gastroenterology, Moscow State University of Medicine and Dentistry; Prof., Department of general medical practice and family medicine, Tver State Medical University.
111123, Moscow, Entuziastov highway, 86, bld. 6
N. N. Dekhnich
Smolensk State Medical University
Russian Federation
Russian Federation
Natalya N. Dekhnich — Dr. Sci. (Med.), Prof., Department of Faculty Therapy; Smolensk State Medical University.
214019, Smolensk, Krupskoy str., 28
N. V. Korochyanskaya
Kuban State Medical University
Russian Federation
Russian Federation
Natalia V. Korochanskaya — Dr. Sci. (Med.), Head of the Gastroenterology Centre, Prof., Chair of Surgery No. 3, Kuban State Medical University; Chief Gastroenterologist of the Ministry of Health of the Krasnodar Territory.
350063, Krasnodar, Mitrofana Sedina str., 4
T. L. Lapina
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Tatiana L. Lapina — Cand. Sci. (Med), Assoc. Prof., Chair of Internal Diseases Propedeutics, Gastroenterology and Hepatology, I.M. Sechenov First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1, bld. 1
E. A. Poluektova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Elena A. Poluektova — Dr. Sci. (Med.), Prof., Chair of Internal Disease Propaedeutics, Gastroenterology and Hepatology; Gastroenterologist, Department of Chronic Intestinal and Pancreatic Diseases, Vasilenko Clinic of Internal Disease Propaedeutics, Gastroenterology and Hepatology Sechenov First Moscow State Medical University (Sechenov University).
119991, Moscow, Pogodinskaya str., 1, bld. 1
V. I. Simanenkov
I.I. Mechnikov North-Western State Medical University
Russian Federation
Russian Federation
Vladimir I. Simanenkov — Dr. Sci. (Med.), Prof., Chair of Internal Diseases, Clinical Pharmacology and Nephrology, I.I. Mechnikov North-West State Medical University.
191015, St.-Petersburg, Kirochnaya str., 41
A. S. Trukhmanov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Aleksandr S. Trukhmanov — Dr. Sci. (Med.), Prof., Department of Internal Disease Propaedeutics, Sechenov First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1, bld. 1
I. B. Khlynov
Ural State Medical University
Russian Federation
Russian Federation
Igor B. Khlynov — Dr. Sci. (Med.), Assoc. Prof., Chair of Intermediate Therapy and Geriatrics, Ural State Medical University.
620028, Ekaterinburg, Repina str., 3
V. V. Tsukanov
Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences, an autonomous branch of the Research Institute of Medical Problems of the North
Russian Federation
Russian Federation
Vladislav V. Tsukanov — Dr. Sci. (Med.), Prof., Head of the Clinical Department of Adult and Infant Digestive Pathology, Research Institute for Medical Problems in the North — Division of Krasnoyarsk Scientific Centre of the Siberian Branch of the RAS.
660022, Krasnoyarsk, Partizana Zheleznyaka str., 3G
A. A. Sheptulin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Arkadiy A. Sheptulin — Dr. Sci. (Med.), Prof., Chair of Internal Diseases Propedeutics, Gastroenterology and Hepatology, Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1, bld. 1
References
1. Sonnenberg A. Epidemiology of Helicobacter pylori. Aliment Pharmacol Ther. 2022;55 (Suppl 1):S—S13. DOI: 10.1111/apt.16592
2. Graham D.Y. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World J Gastroenterol. 2014;20(18):5191—204. DOI: 10.3748/wjg.v20.i18.5191
3. Ivashkin V.T., Mayev I.V., Lapina T.L., Sheptulin A.A., Trukhmanov A.S., Baranskaya E.K., et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Rus J Gastroenterol Hepatol Coloproctology. 2018;28(1):55—70 (In Russ.). DOI: 10.22416/1382-4376-2018-28-1-55-70
4. Bordin D., Morozov S., Plavnik R., Bakulina N., Voynovan I., Skibo I., et al. Helicobacter pylori infection prevalence in ambulatory settings in 2017-2019 in Russia: The data of real-world national multicenter trial. Helicobacter. 2022;27(5):e12924. DOI: 10.1111/hel.12924
5. Health care in Russia. 2021: Statistical compendium. Moscow: Rosstat, 2021 (In Russ.). https://rosstat.gov.ru/storage/mediabank/Zdravoohran-2021.pdf
6. Kaprin A.D., Starinsky V.V., Shakhzadova A.O. (ed.) Malignant neoplasms in Russia in 2020 (morbidity and mortality). Moscow: MNIOI im. P.A. Herzen — a branch of the Federal State Budgetary Institution “NMITs Radiology” of the Ministry of Health of Russia, 2021 (In Russ.).
7. Andreev D.N., Maev I.V., Kucheryavyy Yu.A. Helicobacter pylori resistance in the Russian Federation: a meta-analysis of studies over the past 10 years. Therapeutic Archive. 2020;92(11):24—30 (In Russ.). DOI: 10.26442/00403660.2020.11.000795
8. Malfertheiner P., Megraud F., Rokkas T., Gisbert J.P., Liou J.M., Schulz C., et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022:gutjnl-2022-327745. DOI: 10.1136/gutjnl-2022-327745
9. Kim B.J., Lee H., Lee Y.C. Jeon S.W., Kim G.H., Kim H.S., et al. Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for Helicobacter pylori Infection: A Nationwide Randomized Trial in Korea. Gut Liver. 2019;13(5):531—540. DOI: 10.5009/gnl19136
10. Venneman K., Huybrechts I., Gunter M.J., Vandendaele L., Herrero R., Van Herck K. The epidemiology of Helicobacter pylori infection in Europe and the impact of lifestyle on its natural evolution toward stomach cancer after infection: A systematic review. Helicobacter. 2018;23(3):e12483. DOI: 10.1111/hel.12483
11. Derakhshan M.H., El-Omar E., Oien K., Gillen D., Fyfe V., Crabtree J.E., McColl K.E. Gastric histology, serological markers and age as predictors of gastric acid secretion in patients infected with Helicobacter pylori. J Clin Pathol. 2006;59(12):1293—9. DOI: 10.1136/jcp.2005.036111
12. Bisschops R., Areia M., Coron E., Dobru D., Kaskas B., Kuvaev R., et al. Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy. 2016;48(9):843—64. DOI: 10.1055/s-0042-113128
13. Pimentel-Nunes P., Libanio D., Lage J., Abrantes D., Coimbra M., Esposito G., et al. A multicenter prospective study of the real-time use of narrow-band imaging in the diagnosis of premalignant gastric conditions and lesions. En-doscopy. 2016;48(8):723-30. DOI: 10.1055/s-0042-108435
14. Marcos P., Brito-Gongalves G., Libanio D., Pita I., Castro R., Sa I., et al. Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: can we replace histology assessment also in the West? Gut. 2020;69(10):1762-8. DOI: 10.1136/gutjnl-2019-320091
15. Libanio D., Braga V., Ferraz S., Castro R., Lage J., Pita I., et al. Prospective comparative study of endoscopic submucosal dissection and gastrectomy for early neoplastic lesions including patients' perspectives. Endoscopy. 2019;51(1):30-9. DOI: 10.1055/a-0628-6601
16. Wang Y.H., Li Z., Wang L., Zhu-Ge L.Y., Zhao R.L., et al. A systematic review and meta-analysis of genotypic methods for detecting antibiotic resistance in Helicobacter pylori. Helicobacter. 2018;23(2):e12467. DOI: 10.1111/hel.12467
17. Benejat L., Ducournau A., Lehours P., Megraud F. Real-time PCR for Helicobacter pylori diagnosis. The best tools available. Helicobacter. 2018;23(5):e12512. DOI: 10.1111/hel.12512
18. Chung W.C., Jeon E.J., Oh J.H., Park J.M., Kim T.H., Cheung D.Y., et al. Dual-priming oligonucleotide-based multiplex PCR using tissue samples from the rapid urease test kit for the detection of Helicobacter pylori in bleeding peptic ulcers. Dig Liver Dis. 2016;48(8):899-903. DOI: 10.1016/j.dld.2016.04.012
19. Nyssen O.P., Espada M., Gisbert J.P. Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Front Microbiol. 2022;13:913436. DOI: 10.3389/fmicb.2022.913436
20. Scarpignato C., Hunt R.H. Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers. Curr Treat Options Gastro. 2021;19:94-132. DOI: 10.1007/s11938-020-00330-x
21. Graham D.Y., Lu H., Shiotani A. Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance. J Gastroenterol Hepatol. 2021;36(5):1159-63. DOI: 10.1111/jgh.15252
22. Jung Y.S., Kim E.H., Park C.H. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46(2):106-114. DOI: 10.1111/apt.14130
23. Chen Q., Liang X., Long X., Yu L., Liu W., Lu H. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases. Helicobacter. 2019;24(2):e12563. DOI: 10.1111/hel.12563
24. Ferreira C.N., Serrazina J., Marinho R.T. Detection and Characterization of Early Gastric Cancer. Front Oncol. 2022;12:855216. DOI: 10.3389/fonc.2022.855216
25. Palleja A., Mikkelsen K.H., Forslund S.K., Kashani A., Allin K.H., Nielsen T., et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat Microbiol. 2018;3(11):1255-65. DOI: 10.1038/s41564-018-0257-9
26. Megraud F., Bruyndonckx R., Coenen S., Wittkop L., Huang T.D., Hoebeke M., et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021;70(10):1815-22. DOI: 10.1136/gutjnl-2021-324032
27. Lv Z., Wang B., Zhou X., Wang F., Xie Y., Zheng H., Lv N. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis. Exp Ther Med. 2015;9(3):707-16. DOI: 10.3892/etm.2015.2174
28. Ivashkin V.T., Mayev I.V., Abdulganieva D.I., Alekseenko S.A., Gorelov A.V., Zakharova I.N., et al. Practical Recommendations of Scientific Society for the Study of Human Microbiome and the Russian Gastroenterological Association on Use of Probiotics, Prebiotics, Synbiotics and Functional Foods in Treatment and Prevention of Gastroenterological Diseases in Children and Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(2):65-91 (In Russ.). DOI: 10.22416/1382-4376-2021-31-2-65-91
29. Rumyantseva D.E., Trukhmanov A.S., Kudryavtseva A.V., Krasnov G.S., Paraskevova A.V., Storonova O.A., Ponomarev A.B. Microbiota of the Esophagus and Stomach in Patients with Gastroesophageal Reflux Disease and Healthy Volunteers. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(4):36-46 (In Russ.). DOI: 10.22416/1382-4376-2018-28-4-36-46
30. Sung J.J.Y., Coker O.O., Chu E., Szeto C.H., Luk S.T.Y., Lau H.C.H., Yu J. Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after Helicobacter pylori eradication. Gut. 2020;69(9):1572-80. DOI: 10.1136/gutjnl-2019-319826
31. World Gastroenterology Organization. Probiotics and prebiotics. 2017. https://www.worldgastroenterology.org/guidelines
32. Keikha M., Karbalaei M. Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections. BMC Gastroenterol. 2021;21(1):388. DOI: 10.1186/s12876-021-01977-1
33. Xu W., Xu L., Xu C. Relationship between Helicobacter pylori infection and gastrointestinal microecology. Front Cell Infect Microbiol. 2022;12:938608. DOI: 10.3389/fcimb.2022.938608
34. Zhang M.M., Qian W., Qin Y.Y., He J., Zhou Y.H. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol. 2015;21(14):4345-57. DOI: 10.3748/wjg.v21. i14.4345
35. Shi X., Zhang J., Mo L., Shi J., Qin M., Huang X. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine (Baltimore). 2019;98(15):e15180. DOI: 10.1097/MD.0000000000015180
36. Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32(9):1069-79. DOI: 10.1111/j.1365-2036.2010.04457.x
37. Zhao Y., Yang Y., Aruna, Xiao J., Song J., Huang T., et al. Saccharomyces boulardii Combined With Quadruple Therapy for Helicobacter pylori Eradication Decreased the Duration and Severity of Diarrhea: A Multi-Center Prospective Randomized Controlled Trial. Front Med (Lausanne). 2021;8:776955. DOI: 10.3389/fmed.2021.776955
38. Zhou B.G., Chen L.X., Li B., Wan L.Y., Ai Y.W. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis. Helicobacter. 2019;24(5):e12651. DOI: 10.1111/hel.12651
39. Melit L.E., Marginean C.O., Sasaran M.O. The Challenges of Eradicating Pediatric Helicobacter pylori Infection in the Era of Probiotics. Children (Basel). 2022;9(6):795. DOI: 10.3390/children9060795
40. Suzuki S., Kusano C., Horii T., Ichijima R., Ikehara H. The Ideal Helicobacter pylori Treatment for the Present and the Future. Digestion. 2022;103(1):62—8. DOI: 10.1159/000519413
41. Bai X., Zhu M., He Y., Wang T., Tian D., Shu J. The impacts of probiotics in eradication therapy of Helicobacter pylori. Arch Microbiol. 2022;204(12):692. DOI: 10.1007/s00203-022-03314-w
42. Losurdo G., Cubisino R., Barone M., Principi M., Leandro G., Ierardi E., Di Leo A. Probiotic monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis. World J Gastroenterol. 2018;24(1):139-49. DOI: 10.3748/wjg.v24.i1.139
43. Compare D., Sgamato C., Nardone O.M., Rocco A., Coccoli P., Laurenza C., Nardone G. Probiotics in Gastrointestinal Diseases: All that Glitters Is Not Gold. Dig Dis. 2022;40(1):123-32. DOI: 10.1159/000516023
44. Dinleyici E.C., Kara A., Ozen M., Vandenplas Y. Saccharomyces boulardii CNCM I-745 in different clinical conditions. Expert Opin Biol Ther. 2014;14(11):1593— 609. DOI: 10.1517/14712598.2014.937419
45. Czerucka D., Rampal P. Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections. World J Gastroenterol. 2019;25(18):2188—203. DOI: 10.3748/wjg.v25.i18.2188
46. Terciolo C., Dapoigny M., Andre F. Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption. Clin Exp Gastroenterol. 2019;12:67-82. DOI: 10.2147/CEG.S181590
47. Stier H., Bischoff S.C. Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system. Clin Exp Gastroenterol. 2016;9:269-79. DOI: 10.2147/CEG.S111003
48. Lacotte P.A., Simons A., Bouttier S., Malet-Villemagne J., Nicolas V., Janoir C. Inhibition of In Vitro Clostridioides difficile Biofilm Formation by the Probiotic Yeast Saccharomyces boulardii CNCM I-745 through Modification of the Extracellular Matrix Composition. Microorganisms. 2022;10(6):1082. DOI: 10.3390/microorganisms10061082
49. Cifuentes S.G., Prado M.B., Fornasini M., Cohen H., Baldeon M.E., Cardenas P.A. Saccharomyces boulardii CNCM I-745 supplementation modifies the fecal resistome during Helicobacter pylori eradication therapy. Helicobacter. 2022;27(2):e12870. DOI: 10.1111/hel.12870
50. Selig D.J., DeLuca J.P., Li Q., Lin H., Nguyen K., Scott S.M., et al. Saccharomyces boulardii CNCM I-745 probiotic does not alter the pharmacokinetics of amoxicillin. Drug Metab Pers Ther. 2020;35(1):/j/dmdi.2020.35. issue-1/dmpt-2019-0032/dmpt-2019-0032.xml. DOI: 10.1515/dmpt-2019-0032
51. Cardenas P.A., Garces D., Prado-Vivar B., Flores N., Fornasini M., Cohen H., et al. Effect of Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome. Eur J Clin Microbiol Infect Dis. 2020;39(7):1365-72. DOI: 10.1007/s10096-020-03854-3
Supplementary files
Review
For citations:
Ivashkin V.Т., Ulyanin A.I., Mayev I.V., Kozlov R.S., Livzan M.A., Abdulkhakov S.R., Alekseyeva O.P., Alekseyenko S.A., Bordin D.S., Dekhnich N.N., Korochyanskaya N.V., Lapina T.L., Poluektova E.A., Simanenkov V.I., Trukhmanov A.S., Khlynov I.B., Tsukanov V.V., Sheptulin A.A. Modern Approaches to H. pylori Eradication Therapy in Adults (Literature Review and Resolution of Experts Council). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(6):7-19. https://doi.org/10.22416/1382-4376-2022-32-6-7-19
Views:
1375
Email this article 
